Exploring dark antigens: Enara and Boehringer Ingelheim sign oncology partnership
UK-based Enara Bio has entered into a collaboration with German-headquartered Boehringer Ingelheim. Under the terms of the deal, Enara will...
-
Thermo Fisher ScientificMergers & Acquisitions$874.5M
-
NewAmsterdam PharmaCapital Raising$196M
-
Boehringer IngelheimPartnership$1.06BN
-
SanofiMergers & Acquisitions$1.45BN
-
MerckMergers & AcquisitionsUndisclosed
-
AstraZenecaMergers & Acquisitions$400M
-
COVAXXLicensing AgreementUndisclosed
-
TakedaMergers & Acquisitions$322M
-
ServierMergers & Acquisitions$2BN
-
NovartisMergers & Acquisitions$770M
-
Eli LillyMergers & Acquisitions$1.04BN
-
AstraZenecaMergers & Acquisitions$39BN
-
BoehringerMergers & Acquisitions$1.43BN
-
Gilead SciencesMergers & Acquisitions$1.4BN
-
Boehringer IngelheimMergers & AcquisitionsUndisclosed
-
InovioPartnershipUndisclosed
-
Boston ScientificMergers & Acquisitions$800M
-
TakedaLicensing Agreement$278M
-
BiogenLicensing Agreement$1.525BN
-
MerckMergers & Acquisitions$425M
-
NovartisPartnership$1.3BN
-
BMSMergers & Acquisitions$13.1BN
-
RocheLicensing Agreement$308M
-
TaihoLicensing AgreementUndisclosed
-
MerckMergers & Acquisitions$2.75BN
-
CEPILicensing Agreement$328M
-
HumanigenLicensing Agreement$20M
-
SanofiMergers & Acquisitions$359M
-
Aspen PharmacarePartnershipUndisclosed
-
CStone PharmaceuticalsLicensing Agreement$363.5M
-
![Henogen]()
Thermo Fisher Scientific acquires Novasep’s Henogen for $874.5m
-
![Phesi synthetic control]()
Phesi and Sensyne to collaborate on synthetic control arms for clinical trials
-
![Immuneering]()
Disease-cancelling drugs: Immuneering raises $62m in Series B round
-
![Enara]()
Boehringer enters into cancer drug development deal with Enara Bio
-
![Kymab]()
Sanofi to acquire clinical-stage biopharma firm Kymab for $1.45bn
-
![EY M&A]()
Biopharma M&A: EY analysts optimistic for 2021 deals after a mixed 2020
Submit a deal
Ensure your company's deals are accurately presented to thousands of potential clients by using our deals submission form.
DEALS ANALYSIS
Pharma November deals snapshot
Consolidation in the pharmaceutical sector, with the biggest November deals happening in the US, was given a boost by China last month.
Inhibiting DDR pathways: Artios and the Merck Group team up on oncology drug discovery
DNA damage response (DDR)-focused Artios Pharma has signed a global strategic collaboration with the Merck Group to discover and develop multiple precision cancer drugs.
Targeting ‘undruggable’ proteins: Frontier collaborates with AbbVie
Precision medicine-focused Frontier Medicines has signed a multi-year collaboration with AbbVie to discover, develop and commercialise multiple small molecule therapeutics against difficult-to-drug protein targets.
Applying AI to global health challenges: Gates Foundation awards $4.2m to Exscientia
UK-based artificial intelligence (AI) drug discovery company Exscientia has received a $4.2m two-year grant from the Bill and Melinda Gates Foundation to apply its two Centaur platforms to three global...
Spotlight on rare neurological diseases: Noema closes $60.8m Series A round
Swiss-based Noema Pharma has raised CHF54m ($60.8m) in an oversubscribed Series A round. The funding was co-led by Sofinnova Partners and Polaris Partners; other investors included Gilde Healthcare and BioMed...
Investing in innovative biotechs with Novo Ventures
Founded in the 1990s, the Novo Nordisk Foundation oversees the management and administration of the Novo Group, comprised of Novo Nordisk, the Danish pharma giant renowned for its diabetes research and products,...
SynOx raises €37m in Series A to develop emactuzumab for rare cancer TGCT
Dublin-based biopharma company SynOx has secured €37m in a Series A financing round led by HealthCap and Medicxi. Forbion and Gimv also participated in the financing.
BioMarin and Deep Genomics team up on AI rare disease drug discovery
US rare disease-focused biotech BioMarin has entered a preclinical collaboration with Toronto-based artificial intelligence (AI) company Deep Genomics to discover and develop oligonucleotide drug candidates for four undisclosed rare diseases...
Merck acquires VelosBio: exploring the promise of ROR1 in cancer
Pharma giant Merck has entered into a definitive agreement to acquire oncology biotech VelosBio for $2.75bn in cash. The acquisition remains subject to certain customary adjustments and conditions; the deal...
Spotlight on Zolgensma: REGENXBIO receives $80m from Novartis for AAV vector
Approved in May 2019 for children under two with spinal muscular atrophy (SMA), Novartis’s Zolgensma (onasemnogene abeparvovec) is a transformative, one-time gene therapy that targets the genetic cause of SMA....